ClinicalTrials.gg
CompletedNCT01746680TIARAUpdated Aug 11, 2015

Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis

A Phase 4 interventional study of Tacrolimus with Methotrexate in Rheumatoid Arthritis, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-11.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
60th of 113
111 · median 130
Started
2012
with 10 others
Phase 4
38 of 113
3 open now
Registered
69th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 60th largest by enrollment, is one of 11 that started in 2012, is one of 38 in phase 4, and was the 69th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The aims of this study are to assess the efficacy and safety of tacrolimus in patients with active rheumatoid arthritis(RA). EULAR(European League Against Rheumatism) response at week 24 compared to baseline will be evaluated to assess the efficacy of Tacrolimus.

Read the detailed description

A Phase IV, Open labeled, Multi-Center Trial to Assess the Efficacy and Safety of Tacrolimus(Tacrobell®)in patients with active rheumatoid arthritis(RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis
  • RA
  • tacrolimus
  • Disease Activity Score 28
  • EULAR
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥20years
  • Signed and dated document indicating that the patient
  • Women of must have a negative serum or urine pregnancy test at the screening visit. Except in the case of surgically sterile or amenorrhea for one year.
  • Female patients must agree to use adequate measures during the period of therapy which should be continued for 4 weeks.
  • have RA and meet all of the following criteria; RA occurring ≥ 3months and less than 15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis; Active RA patients with MTX and among them who has insufficiency response to DMARDs as defined DAS28>3.2 in active RA patient. Insufficiency response is defined despite MTX therapy for > 12 weeks, RA activity≥ more than moderate and confirmable during 12 weeks, sequence of taking MTX >7.5mg/week for more than 6 weeks; ESR≥28mm/h or CRP≥1.0mg/dl; Tender Joint Counts must be more than 6 and Swollen Joint Counts must be more than 3

Exclusion criteria

Exclusion Criteria:

  • Inflammatory joint diseases, Systematic inflammatory disease
  • Prosthesis and had an event of infected in it.
  • Medical history of chronic infection, moderate infection or possibly to life threatening or signs and symptoms of serious infection.
  • Patients have received treatment with a from baseline within 8 weeks.
  • positive and virus positive patient.
  • Patients have a history of . (But, carcinoma in situ of the uterine cervix or basal cell carcinoma have been treated is allowed within 5years)
  • Patients have cardiovascular disease or associated disease which is not controlled.
  • uncontrollable blood sugar( ≥8%) or required insulin.
  • Patients with a history of operation on index knee joint which could have influence on the result and need to have surgery as determined by investigator.
  • At screening, patients have laboratory result as defined by ; white blood cell(WBC) \< 3,500/mm3, (ANC) \< 1,500/mm3, \< 8.5g/dl, count(PLT) \< 100,000/mm3, Serum creatinine >1.5* or 2mg/dl, Total > 2*upper limit of normal, (AST) > 2*upper limit of normal, alanine aminotransferase(ALT) > 2*upper limit of normal, alkaline phosphatase(ALP) > 2*upper limit of normal
  • Patients on any other clinical trial or experimental treatment in the past 8weeks
  • An impossible one who participates in clinical trial by investigator's decision
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Tacrolimus with Methotrexate

    Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0\~4 weeks, 2mg for 4 weeks\~8 weeks, 3mg for 8 weeks\~24 weeks

    Drug: Tacrolimus with Methotrexate

Interventions

  • DrugTacrolimus with Methotrexate

    Drug pages: Tacrolimus · Methotrexate

    Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week

    Also known as: TacroBell® with MTX

06

What researchers measure

Primary outcomes

  1. Change from baseline European League Against Rheumatism(EULAR) response at 24weeks

    Time frame: baseline, 24weeks

Secondary outcomes

  1. Change from baseline Simplified Disease Activity Index(SDAI) at 24weeks

    Time frame: baseline, 24weeks

  2. Change from baseline Korean Health Assessment Questionnaire(KHAQ-20) at 24weeks

    Time frame: baseline, 24weeks

  3. Change from baseline Erythrocyte Sedimentation Rate(ESR) at 16weeks

    Time frame: baseline, 16weeks

  4. Change from baseline Erythrocyte Sedimentation Rate(ESR) at 24weeks

    Time frame: baseline, 24eeks

  5. Change from baseline C-Reactive Protein(CRP) at 16weeks

    Time frame: baseline, 16weeks

  6. Change from baseline C-Reactive Protein(CRP) at 24weeks

    Time frame: baseline, 24weeks

  7. Change from baseline European League Against Rheumatism(EULAR) response at 16weeks

    Time frame: baseline, 16weeks

07

Study locations

1 site
  • Kyung Hee University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2012
First posted
Dec 11, 2012
Start
Aug 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Aug 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01746680
Responsible party
Sponsor
First posted
Dec 11, 2012
Start date
Aug 2012
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Aug 11, 2015

Study contacts

Seung -Jae Hong, phD, Dr
study chair · Kyung Hee University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Methotrexate

Start the discussion